Table 1.
Patient No. | Age | Plt. Count, (× 10∧9/L) | Fibrosis | WBC (× 10∧9/L) | Splenomegaly | TET2 | ASXL1 | JAK2 V617F | MPL W515L | pSTAT5 | Cytogenetics | SNP-A karyotyping | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gain | Loss | UPD | ||||||||||||
1*†‡ | 78 | 277§ | 2+ | 19.5 | N | - | - | - | + | + | 46,XY[20] | - | - | - |
2*† | 73 | 664 | 2+ | 10.14 | Y | delC 1480Sfs | NA | - | - | + | 46,XY[20] | - | - | - |
3† | 79 | 660 | 4+ | 23.84 | Y | - | - | + | + | + | 46,XX,inv(9)(p11;q12)[20] | - | 2p16.2; 22q11.23 | 1p11.2p-ter |
4† | 76 | 587 | 1+ | 28.06 | Y | - | - | + | - | + | 46,XY[20] | - | - | 9p13.1-pter |
5† | 71 | 766 | 4+ | 26.2 | Y | - | L1395V | - | - | + | 46,XY[20] | - | - | - |
6† | 57 | 600 | 4+ | 37.09 | Y | - | - | + | - | + | 46,XX[20] | - # | - # | - # |
7† | 78 | 894 | 2+ | 3.81 | N | - | - | + | - | + | 46,XX[20] | - | - | - |
8† | 58 | 771 | 0 | 9.99 | N | - | - | - | - | + | 46,XX[20] | - | - | - |
9† | 87 | 625 | 2+ | 15.4 | Y | - | - | - | + | + | 46,XY[20] | - | - | 1p13.3-pter 2p12-pter 6p21.2-p22.1 6p16.3-q22.33 8p21.3-q24.13 10p13-p14 |
10† | 78 | 483 | NA | 22.48 | N | - | - | - | - | + | 46, XY,inv(3)(q21;q26.2)[20] | 11p25 | - | - |
11*†‡ | 61 | 329π | 2+ | 90.34 | Y | - | - | + | - | + | 46,XY[20] | - | - | - |
12*† | 85 | 598 | 1+/2+ | 21.8 | N | - | NA | + | - | + | 46,XX[20] | 7q21.2 | - | - |
13† | 71 | 496 | 0 | 4.14 | N | - | NA | + | - | NA | 5q- | 20q13.12 | - | 1p32-pter |
14*† | 72 | 512 | 0 | 8.1 | N | - | - | + | - | NA | 45,X,inv(10)(q21.2;q24.3)[3] 46,XX,inv(10)(q21.2;q24.3)[17] |
- | - | - |
15† | 66 | 773 | NA | 5.39 | N | - | - | - | - | - | 45,X,-X[4]/46,XX[16] | 2p11.23 | Xq25 | - |
16† | 69 | 616 | 2+ | 4.26 | Y | NA | - | - | - | - | 46,XY,del(5)(q22;q33)[20] | - | 5q21.1q31.3 | 1p35.1-pter |
17† | 63 | 611 | 0 | 4.99 | N | - | - | - | - | - | 46,XX[20] | 21q22.3 | - | - |
18†‡ | 73 | 667 | 2+ | 33.46 | N | V1718L | - | - | - | - | 47,XX,+8[20] | 8 | - | - |
19 | 83 | 469 | NA | 4.6 | N | - | Q1102D | - | - | NA | 46,XX[20] | NA | NA | NA |
20 | 63 | 614 | NA | 14.36 | Y | - | - | - | - | - | 46,XX[20] | - | - | 2p22.3-pter 3q21.3qter |
21 | 61 | 457 | 0 | 5.79 | N | - | - | - | - | - | 46,XX,add(15)(p11.1),add(22)(p11.2)[3]/47,idem, +19 [19] | +19 | - | - |
22 | 83 | 636 | 1+ | 5.30 | N | - | - | - | - | - | 46,XY[20] | - | - | - |
23 | 80 | 761 | 0 | 8.27 | N | - | - | - | - | NA | 46,XX[20] | - | - | 3q21.3qter |
Patients were part of a previous series where mutation analysis was confined to JAK2 V617F/MPL W515L mutations and pSTAT5 analysis [1,11,15]; NA - not available;
documented history of thrombocytosis over previous 6 months (to 1353×109/l);
documented history of thrombocytosis over previous 6 months (546–1213×109/l);
used 50K array.